Literature DB >> 33645550

Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration.

Anne Winkler1, Claudia Wrzos1, Michael Haberl2, Marie-Theres Weil3,4, Ming Gao5, Wiebke Möbius3,4, Francesca Odoardi2, Dietmar R Thal6,7, Mayland Chang5, Ghislain Opdenakker8, Jeffrey L Bennett9, Stefan Nessler1, Christine Stadelmann1.   

Abstract

Approximately 80% of neuromyelitis optica spectrum disorder (NMOSD) patients harbor serum anti-aquaporin-4 autoantibodies targeting astrocytes in the CNS. Crucial for NMOSD lesion initiation is disruption of the blood-brain barrier (BBB), which allows the entrance of Abs and serum complement into the CNS and which is a target for new NMOSD therapies. Astrocytes have important functions in BBB maintenance; however, the influence of their loss and the role of immune cell infiltration on BBB permeability in NMOSD have not yet been investigated. Using an experimental model of targeted NMOSD lesions in rats, we demonstrate that astrocyte destruction coincides with a transient disruption of the BBB and a selective loss of occludin from tight junctions. It is noteworthy that BBB integrity is reestablished before astrocytes repopulate. Rather than persistent astrocyte loss, polymorphonuclear leukocytes (PMNs) are the main mediators of BBB disruption, and their depletion preserves BBB integrity and prevents astrocyte loss. Inhibition of PMN chemoattraction, activation, and proteolytic function reduces lesion size. In summary, our data support a crucial role for PMNs in BBB disruption and NMOSD lesion development, rendering their recruitment and activation promising therapeutic targets.

Entities:  

Keywords:  Demyelinating disorders; Neuroscience; Neutrophils; Tight junctions

Year:  2021        PMID: 33645550      PMCID: PMC7919716          DOI: 10.1172/JCI141694

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  84 in total

1.  An improved in vitro blood-brain barrier model: rat brain endothelial cells co-cultured with astrocytes.

Authors:  N Joan Abbott; Diana E M Dolman; Svetlana Drndarski; Sarah M Fredriksson
Journal:  Methods Mol Biol       Date:  2012

2.  Pericytes regulate the blood-brain barrier.

Authors:  Annika Armulik; Guillem Genové; Maarja Mäe; Maya H Nisancioglu; Elisabet Wallgard; Colin Niaudet; Liqun He; Jenny Norlin; Per Lindblom; Karin Strittmatter; Bengt R Johansson; Christer Betsholtz
Journal:  Nature       Date:  2010-10-13       Impact factor: 49.962

Review 3.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

4.  Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases.

Authors:  Benoit Aubé; Sébastien A Lévesque; Alexandre Paré; Émilie Chamma; Hania Kébir; Roser Gorina; Marc-André Lécuyer; Jorge I Alvarez; Yves De Koninck; Britta Engelhardt; Alexandre Prat; Daniel Côté; Steve Lacroix
Journal:  J Immunol       Date:  2014-07-21       Impact factor: 5.422

5.  Cytokine-induced acute inflammation in the brain and spinal cord.

Authors:  L Schnell; S Fearn; M E Schwab; V H Perry; D C Anthony
Journal:  J Neuropathol Exp Neurol       Date:  1999-03       Impact factor: 3.685

6.  Spatiotemporal distribution of fibrinogen in marmoset and human inflammatory demyelination.

Authors:  Nathanael J Lee; Seung-Kwon Ha; Pascal Sati; Martina Absinta; Nicholas J Luciano; Jennifer A Lefeuvre; Matthew K Schindler; Emily C Leibovitch; Jae Kyu Ryu; Mark A Petersen; Afonso C Silva; Steven Jacobson; Katerina Akassoglou; Daniel S Reich
Journal:  Brain       Date:  2018-06-01       Impact factor: 13.501

7.  Caveolin1 Is Required for Th1 Cell Infiltration, but Not Tight Junction Remodeling, at the Blood-Brain Barrier in Autoimmune Neuroinflammation.

Authors:  Sarah E Lutz; Julian R Smith; Dae Hwan Kim; Carl V L Olson; Kyle Ellefsen; Jennifer M Bates; Sunil P Gandhi; Dritan Agalliu
Journal:  Cell Rep       Date:  2017-11-21       Impact factor: 9.423

Review 8.  Development, maintenance and disruption of the blood-brain barrier.

Authors:  Birgit Obermeier; Richard Daneman; Richard M Ransohoff
Journal:  Nat Med       Date:  2013-12-05       Impact factor: 53.440

9.  Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice.

Authors:  Takehiro Nitta; Masaki Hata; Shimpei Gotoh; Yoshiteru Seo; Hiroyuki Sasaki; Nobuo Hashimoto; Mikio Furuse; Shoichiro Tsukita
Journal:  J Cell Biol       Date:  2003-05-12       Impact factor: 10.539

10.  Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study.

Authors:  Manabu Araki; Takako Matsuoka; Katsuichi Miyamoto; Susumu Kusunoki; Tomoko Okamoto; Miho Murata; Sachiko Miyake; Toshimasa Aranami; Takashi Yamamura
Journal:  Neurology       Date:  2014-03-14       Impact factor: 9.910

View more
  4 in total

Review 1.  Treating Metastatic Brain Cancers With Stem Cells.

Authors:  Nadia Sadanandan; Alex Shear; Beverly Brooks; Madeline Saft; Dorothy Anne Galang Cabantan; Chase Kingsbury; Henry Zhang; Stefan Anthony; Zhen-Jie Wang; Felipe Esparza Salazar; Alma R Lezama Toledo; Germán Rivera Monroy; Joaquin Vega Gonzales-Portillo; Alexa Moscatello; Jea-Young Lee; Cesario V Borlongan
Journal:  Front Mol Neurosci       Date:  2021-11-24       Impact factor: 5.639

Review 2.  Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.

Authors:  Edgar Carnero Contentti; Jorge Correale
Journal:  J Neuroinflammation       Date:  2021-09-16       Impact factor: 8.322

3.  A new form of axonal pathology in a spinal model of neuromyelitis optica.

Authors:  Marina Herwerth; Selin Kenet; Martina Schifferer; Anne Winkler; Melanie Weber; Nicolas Snaidero; Mengzhe Wang; Melanie Lohrberg; Jeffrey L Bennett; Christine Stadelmann; Bernhard Hemmer; Thomas Misgeld
Journal:  Brain       Date:  2022-06-03       Impact factor: 15.255

4.  Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.

Authors:  Friedemann Paul; Carmen Infante-Duarte; Maria Schroeder-Castagno; Alba Del Rio-Serrato; Andreas Wilhelm; Silvina Romero-Suárez; Patrick Schindler; Cesar Alvarez-González; Ankelien-Solveig Duchow; Judith Bellmann-Strobl; Klemens Ruprecht; Maria Hastermann; Gerald Grütz; Brigitte Wildemann; Sven Jarius; Tanja Schmitz-Hübsch
Journal:  J Neuroinflammation       Date:  2022-10-01       Impact factor: 9.587

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.